Article thumbnail

A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.

By I.A. Voutsadakis and A. Cairoli

Abstract

Abstract The 5q deletion is a chromosomal abnormality that is observed in a subset of myelodysplastic syndromes (MDS). When isolated, this abnormality defines a specific clinical syndrome termed MDS associated with isolated deletion 5q, presenting with macrocytic anemia, normal platelet count or slight thrombocytosis, hypolobated megakaryocytes and fewer than 5% blasts in the bone marrow. MDS with the 5q deletion have a particular sensitivity to treatment with lenalidomide, a thalidomide analog. In this article, molecular changes in 5q- MDS derived from haploinsufficiency of genes encoded from the deleted region in 5q are reviewed, and mechanisms that link these molecular lesions with lenalidomide sensitivity are proposed

Publisher: 'Informa UK Limited'
Year: 2012
DOI identifier: 10.3109/10428194.2011.623255
OAI identifier: oai:serval.unil.ch:BIB_7F19DEDF7765
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://serval.unil.ch/notice/... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.